No Data
OmniAb, Inc. (NASDAQ:OABI) Shares Could Be 32% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for OmniAb is US$6.78 based on 2 Stage Free Cash Flow to Equity Current share price of US$4.60 suggests OmniAb is potentially 32% undervalued The US$9.88 ana
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb, the Company's novel transgenic chicken platform launched in 2023 that generates fully human and
Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 34%?
OmniAb(OABI.US) Officer Buys US$1.06 Million in Common Stock
$OmniAb(OABI.US)$ Officer FOEHR MATTHEW W purchased 240K shares of common stock on May 24, 2024 at an average price of $4.416 for a total value of $1.06 million.Source: Announcement What is statement
Omniab Insider Bought Shares Worth $1,059,840, According to a Recent SEC Filing
Matthew W Foehr, Director, President and CEO, on May 24, 2024, executed a purchase for 240,000 shares in Omniab (OABI) for $1,059,840. Following the Form 4 filing with the SEC, Foehr has control over
OmniAb to Participate in the Jefferies Global Healthcare Conference
OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be